Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087768 | 0.89 | ALDH1A1 (0.42) | KMT2ALMNAMEN1KCNMA1SMN1; SMN2 | |
| SCHEMBL4894367 | 0.85 | DHODH (0.43) | KMT2ALMNASMN1; SMN2MAPK1 | |
| SCHEMBL14087736 | 0.83 | SMN1; SMN2 (0.50) | KMT2ALMNAMEN1SMN1; SMN2MAPK1 | |
| SCHEMBL4884230 | 0.81 | MAPT (0.43) | KMT2AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL4895411 | 0.81 | ALDH1A1 (0.45) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL4894181 | 0.79 | ALDH1A1 (0.46) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL4887023 | 0.79 | GABRP (0.51) | KMT2ALMNAMEN1MAPTSMN1; SMN2 | |
| SCHEMBL4893232 | 0.78 | PKM (0.45) | KMT2ALMNAMEN1SMN1; SMN2MAPK1 | |
| SCHEMBL4896054 | 0.78 | LMNA (0.48) | KMT2ALMNAMEN1MAPTSMN1; SMN2 | |
| SCHEMBL4886969 | 0.78 | SMN1; SMN2 (0.48) | KMT2ALMNAMEN1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | KMT2A 2650/4885LMNA 3432/4885MEN1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.